39640048|t|Targeted Liposomal Co-Delivery Dopamine with 3-n-Butylphthalide for Effective Against Parkinson's Disease in Mice Model.
39640048|a|Introduction: Parkinson's disease (PD) is a multifactor-induced neurodegenerative disease with high incidence in the elderly population. We found for the first time that the combination of dopamine (DA) and 3-n-butylphthalide (NBP) has great potential for the synergistic treatment of PD. To further improve the therapeutic performance of the drugs, a brain-targeting liposomal co-delivery system encapsulating NBP and DA ((NBP+DA)-Lips-RVG29) was designed using a rabies virus polypeptide with 29 amino acids (RVG29) as the targeting ligand. Methods: The synergistic neuroprotective effects of NBP and DA were assessed in 6-OHDA-induced PC12 cells. Then, (NBP+DA)-Lips-RVG29 loading with NBP and DA at an optimal ratio was prepared using the thin-film hydration and sonication method. The physicochemical and biological characterization of (NBP+DA)-Lips-RVG29 were systemically investigated, and the therapeutic efficiency and underlying mechanisms of (NBP+DA)-Lips-RVG29 were also explored in vitro and in vivo. Finally, the safety of (NBP+DA)-Lips-RVG29 was evaluated. Results: The synergistic effects of NBP and DA peaked at 1:1 (NBP/DA, mol/mol). The functionalized liposomes showed significantly higher uptake efficiency and blood-brain barrier (BBB) penetration efficiency in vitro. After systemic administration, (NBP+DA)-Lips-RVG29 prolonged the blood circulation of drugs, enhanced BBB penetration and increased drug accumulation in the striatum, substantia nigra and hippocampus. Moreover, (NBP+DA)-Lips-RVG29 showed excellent neuroprotective effects in a cellular PD model of PC12 cells and improved therapeutic efficacy in a PD mouse model. Furthermore, the safety evaluation of (NBP+DA)-Lips-RVG29 revealed no systemic toxicity. Conclusion: NBP and DA exhibited the synergistic anti-PD effects. The RVG29-modified liposomes encapsulating NBP and DA contributed to the accumulation of drugs in the brain lesions area of PD and further improved treatment efficacy. Therefore, (NBP+DA)-Lips-RVG29 represents a promising strategy for the treatment of PD and other neurodegenerative diseases.
39640048	31	39	Dopamine	Chemical	MESH:D004298
39640048	45	63	3-n-Butylphthalide	Chemical	MESH:C027125
39640048	86	105	Parkinson's Disease	Disease	MESH:D010300
39640048	109	113	Mice	Species	10090
39640048	135	154	Parkinson's disease	Disease	MESH:D010300
39640048	156	158	PD	Disease	MESH:D010300
39640048	185	210	neurodegenerative disease	Disease	MESH:D019636
39640048	310	318	dopamine	Chemical	MESH:D004298
39640048	320	322	DA	Chemical	MESH:D004298
39640048	328	346	3-n-butylphthalide	Chemical	MESH:C027125
39640048	348	351	NBP	Chemical	MESH:C027125
39640048	406	408	PD	Disease	MESH:D010300
39640048	532	535	NBP	Chemical	MESH:C027125
39640048	540	542	DA	Chemical	MESH:D004298
39640048	545	548	NBP	Chemical	MESH:C027125
39640048	549	551	DA	Chemical	MESH:D004298
39640048	558	563	RVG29	Chemical	-
39640048	586	598	rabies virus	Species	11292
39640048	632	637	RVG29	Gene	
39640048	716	719	NBP	Chemical	MESH:C027125
39640048	724	726	DA	Chemical	MESH:D004298
39640048	744	750	6-OHDA	Chemical	MESH:D016627
39640048	759	763	PC12	CellLine	CVCL:0481
39640048	778	781	NBP	Chemical	MESH:C027125
39640048	782	784	DA	Chemical	MESH:D004298
39640048	791	796	RVG29	Gene	
39640048	810	813	NBP	Chemical	MESH:C027125
39640048	818	820	DA	Chemical	MESH:D004298
39640048	963	966	NBP	Chemical	MESH:C027125
39640048	967	969	DA	Chemical	MESH:D004298
39640048	976	981	RVG29	Chemical	-
39640048	1075	1078	NBP	Chemical	MESH:C027125
39640048	1079	1081	DA	Chemical	MESH:D004298
39640048	1088	1093	RVG29	Chemical	-
39640048	1159	1162	NBP	Chemical	MESH:C027125
39640048	1163	1165	DA	Chemical	MESH:D004298
39640048	1172	1177	RVG29	Chemical	-
39640048	1229	1232	NBP	Chemical	MESH:C027125
39640048	1237	1239	DA	Chemical	MESH:D004298
39640048	1255	1258	NBP	Chemical	MESH:C027125
39640048	1259	1261	DA	Chemical	MESH:D004298
39640048	1443	1446	NBP	Chemical	MESH:C027125
39640048	1447	1449	DA	Chemical	MESH:D004298
39640048	1456	1461	RVG29	Chemical	-
39640048	1623	1626	NBP	Chemical	MESH:C027125
39640048	1627	1629	DA	Chemical	MESH:D004298
39640048	1636	1641	RVG29	Chemical	-
39640048	1697	1699	PD	Disease	MESH:D010300
39640048	1709	1713	PC12	CellLine	CVCL:0481
39640048	1759	1761	PD	Disease	MESH:D010300
39640048	1762	1767	mouse	Species	10090
39640048	1814	1817	NBP	Chemical	MESH:C027125
39640048	1818	1820	DA	Chemical	MESH:D004298
39640048	1827	1832	RVG29	Chemical	-
39640048	1854	1862	toxicity	Disease	MESH:D064420
39640048	1876	1879	NBP	Chemical	MESH:C027125
39640048	1884	1886	DA	Chemical	MESH:D004298
39640048	1918	1920	PD	Disease	MESH:D010300
39640048	1934	1939	RVG29	Chemical	-
39640048	1973	1976	NBP	Chemical	MESH:C027125
39640048	1981	1983	DA	Chemical	MESH:D004298
39640048	2032	2045	brain lesions	Disease	MESH:D001927
39640048	2054	2056	PD	Disease	MESH:D010300
39640048	2110	2113	NBP	Chemical	MESH:C027125
39640048	2114	2116	DA	Chemical	MESH:D004298
39640048	2123	2128	RVG29	Chemical	-
39640048	2182	2184	PD	Disease	MESH:D010300
39640048	2195	2221	neurodegenerative diseases	Disease	MESH:D019636
39640048	Negative_Correlation	MESH:C027125	MESH:D010300
39640048	Cotreatment	MESH:C027125	MESH:D004298
39640048	Negative_Correlation	MESH:D004298	MESH:D010300

